Blood Advances · 2019 · 38 citations · 48 references
Life SciencesImmunologyPathologyImmunopathologyImmunoregulationImmunotherapyCell-mediated ImmunityImmune Checkpoint InhibitorsImmune HomeostasisImmune RegulationRegulatory T CellsT Cell BiologyHomeostatic ReservePd-1 SignalingPeripheral Immune HomeostasisProgrammed Cell Death Protein 1 (Pd-1) PathwayT Cell Effector FunctionsTreg Cell Homeostasis
Graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a significant cause of morbidity and mortality. Regulatory T cells (Tregs) are critical mediators of immune tolerance after allo-HSCT. Clinical studies have indicated that programmed cell death 1 (PD-1) blockade before allo-HSCT involves a risk of severe GVHD. However, the mechanisms underlying GVHD induction resulting from PD-1 blockade remain unclear. We investigated the impact of PD-1 expression of donor T cells on T-cell reconstitution and GVHD using murine models. We first demonstrated that inhibition of PD-1 signaling induced aggressive expansion of CD4+ conventional T cells; however, Tregs could not maintain expansion because of high susceptibility to apoptosis, resulting in discordant immune recovery and subsequent development of severe GVHD. We then evaluated the impact of posttransplantation cyclophosphamide (PTCy) on abnormal T-cell reconstitution after PD-1 blockade. PTCy efficiently ameliorated GVHD after transplantation from a PD-1-/- donor and extended overall survival by safely regulating the proliferation and apoptosis of T-cell subsets. Notably, in the first 2 weeks after administration of PTCy, Tregs regained their ability to continuously proliferate, resulting in well-balanced reconstitution of donor T-cell subsets. In conclusion, the influence of PD-1 blockade differed within T-cell subsets and caused unbalanced reconstitution of T-cell subsets, resulting in severe GVHD. PTCy successfully restored T-cell homeostasis and ameliorated GVHD induced by PD-1-/- donor T cells. These findings may help explain the pathophysiology behind the observation that PTCy may mitigate the incidence and impact of GVHD associated with prior exposure to PD-1 blockade.
48
Jung‐Hyun Park, Stanley Adoro, Terry I. Guinter et al. · Nature Immunology · 2010 · 5.8K citations · Full text
Shimon Sakaguchi, N Sakaguchi, M Asano et al. · The Journal of Immunology · 1995 · 5.5K citations
Life Sciences, Immunology, Pathology +17
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Lu Zhang, Jianghao Xu, Xuan Zhang et al. · Cellular Physiology and Biochemistry · 2017 · 4.1K citations · Full text
Medicine, Cancer Biology, Oncology +16
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text
Medicine, Oncology, Pharmacology +17